Cadherins are a family of calcium-dependent, cell-cell adhesion mole cules that play an important morphoregulatory role in a wide variety of tissues. Alterations in cadherin function have been implicated in tumor progression in a number of adenocarcinomas. Despite the increasing number of new cadherins identified, little Is known about cadherins in normal renal tissue and renal carcinomas. A novel cadherin transcript, cadherin-6, was recently described to be present in renal cancer cell lines and fetal kidney, but no data on protein expression nor tissue localization has been reported.
INTRODUCTION
Renal cell cancer accounts for approximately 3% of all adult malignancies.
Surgical treatment is an effective therapy only in early stage renal tumors. Advanced stages of renal neoplasms are associated with poor prognoses, because these malignancies are typically refrac tory to chemo-and radiotherapy. Immunotherapy, both active and passive protocols, demonstrate partial and complete remission in a limited subset of patients (1, 2) . Prognostic markers are needed to identify patients who are at risk for recurrence and metastasis of renal cell carcinoma and, thus, would benefit from additional therapeutic modalities. Current prognostic factors like tumor grade, renal vein involvement, and extension to regional lymph nodes are of limited value in this respect (3) . Cadherins, a family of cell-cell adhesion molecules, have demon strated their utility as prognostic markers in a variety of neoplasms. Dysfunction of cadherins has a major impact in the progression of epithelial tumors (4) . Loss or abnormal expression of cadherins in tumors can lead to tumor invasion and disease progression, as dem onstrated for E-cadherin expression in prostate (5), stomach (6),
Ismaninger St. 22, 81675 Munich, Germany. bladder (7), breast (8) , cervical cancer (9) , and other tumors. Similar results have been demonstrated for P-cadherin, for example in breast cancer (8) , gingival carcinomas (10) , and gastric neoplasms (6) .
Studies of the role of abnormal cadherin expression as a marker in renal cell carcinoma progression are less conclusive. Although the proximal tubular cell is thought to be the cellular origin of the majority of renal cell carcinomas, the pattern of cadherin expression in the normal proximal tubule epithelium is not well understood (1 1â€"13). Interestingly, for E-cadherin, which has been shown to be expressed in a high proportion of low grade renal carcinomas (I 4), the expression pattern failed to correlate with disease progression ( I5, 16). Normally, E-cadherin expression is restricted to the distal renal tubules and collecting ducts (17) . N-cadherin, a cell adhesion mole cule found in a variety of different tissues, is expressed during fetal development in renal tissue and is found in the adult kidney only in the proximal renal tubule (18) . However, N-cadherin expression in renal cell cancer also failed to show a correlation with tumor progres sion. Tani et a!. (16) suggested that another unknown cadherin may be important in these tumors. Shimoyama et a!. (19) reported that cadherin-6, a newly identified cadherin molecule, is involved in the development of the kidney. In adult renal tissue, however, only faint or negligible expression of cadherin-6 mRNA could be demonstrated (19, 20) . Neither protein expression nor tissue localization of cadherin-6 was examined in these studies. Shimazui et a!. (21) reported a complex pattern of cadherin mRNA expression in different renal cancer cell lines. This finding suggested the involvement of several cadherins in renal tumors (21) . In this study, we focused upon cadherins that may play a role in the cell-cell adhesion in the proximal renal tubular epithelium and, there fore, possibly may be involved in invasion and progression of renal cell cancer. We demonstrate for the first time that cadherin-6 expres sion occurs only in proximal renal tubules of the normal kidney. Furthermore, in an evaluation of a series of primary renal cell carci nomas, we find that cadherin-6 expression is frequently altered in tumors with histologies associated with poor prognosis.
MATERIALS AND METHODS
Surgical Specimens. Fresh renal tissue was obtained at the time of surgery at The Johns Hopkins Hospital. The specimens were immediately frozen in liquid nitrogen and stored at â€"70Â°C. Frozen sections were cut at a thickness of 6 ,.@m, mounted on poly-L-lysine-coated slides, air dried for 30 mm, and used FBS, L-glutamine, penicillin, streptomycin, and tryptose phosphate as de scribed previously (22) . Northern Analysis. ForNorthernanalysisof cadherin-6mRNA, a random prime-labeled sequence corresponding to nucleotides from position 2108 to 2323, according to the cDNA sequence published by Shimoyama el a!. (19) was used as a probe as described previously (23) . Multitissue blots [2 @.tg of poly(A) mRNA eachi obtained from Clonetech Laboratories (Palo Alto, CA) were probed using the methodology described previously (24) .
Antibodies. A rabbit polyclonal anti-cadherin-6 antibody was generated against a sequence in the intracytoplasmic domain of cadherin-6 as described (25) . This 15-mer (NH2 terminal-RRTPTARDNTDVRDF-COOH terminal) is unique by search at the National Center for Biotechnology Information using BLAST networkservice (26) for cadherin-6in humansandK-cadherinin rats.
Anti-E-cadherin clone 36 is a mouse monoclonal antibody (Transduction Laboratories, Lexington, KY) described previously (27) . 13A9 and 105 are mouse monoclonal antibodies against N-cadherin and a-catenin, respectively (28) . Anti-@3-catenin clone 14 is a mouse monoclonal antibody (Transduction Laboratories), which is described elsewhere (29 
CO2.humidifiedatmosphere). Aftertwo washesin HBSS, cells wereextracted
in TNC with 2% Triton X-lOO, 10 mM phenylmethylsulfonyl fluoride, and 50
,.@g/ml leupeptin for 5 mm at 4Â°C. Cells were scraped. homogenized (10 strokes in a steel dounce), and centrifuged for 50 mm at 100,000 X g at 4Â°C. Two hundred ,.d of the supernatant were incubated with either cadherin-6 (2 @l), a-catenin (100 Ml).f3-catenin(1 pg). or culture medium as a control overnight on ice. Immunocomplexes were captured by Protein G-Plus/Protein A agarose beads (Oncogene Science, Cambridge, MA) and washed twice in extraction buffer. Immunocomplexes were eluted from capture resin in SDS sample buffer (2% SDS, 1.25% @3-mercaptoethanol) and separated by 10% SDS PAGE (0.75-mm gels). The gel was stained and destained as described (24) .
Autoradiographs were exposed at â€"70Â°C. For immunoconcentration experi ments, cells were grown in 175 culture flasks and processed as above, except radioactive labeling was omitted.
Immunoblotting. Frozen renal tissue stored at â€" 70Â°C or 80% confluent cell cultures were lysed in 2% SDS, 100 nmi NaCI, 1 nmi EDTA, and 62.5 m@i the primary antibody at a dilution of 1:10,000for cadherin-6 and 0.5 @.tg/ml for f3-catenin for 3 h at room temperature in Tris-saline buffer with 0.1% nonfat dry milk. As a secondary antibody, horseradish peroxidase-conjugated IgG 
RESULTS
Cadherin-6 mRNA Is Restricted to the Kidney. In an effort to characterize cadherin expression in a neonatal prostate epithelial cell line, we cloned a novel cadherin cDNA using degenerate PCR tech nology (32) . A homology search revealed that the sequence of this cadherin was identical to that of cadherin-6, recently characterized by Shimoyama et a!. (19) to be present in some renal carcinoma lines and in fetal kidney tissue. The localization of expression of cadherin-6 in the normal kidney as well as the possible alterations of cadhenn-6 expression in renal cell cancer was not determined in this previous study. By Northern analysis we confirmed the tissue specificity of cad herin-6, because the analysis of 16 different adult tissues demon strated detectable mRNA message only for kidney. In this tissue, three transcripts of about 3.6, 4.0, and 8 kb were observed (Fig. 1A) . All other tissues, including normal adult prostate, were negative.
Characterization of the Cadherin-6 Antibody. To more fully characterize the expression pattern of cadherin-6 in both normal and neoplastic renal tissues, we developed a polyclonal antiserum against cadherin-6. A unique peptide sequence located in the cytoplasmic domain of cadherin-6 was used as the antigen.
The specificity of this antibody was assessed by immunoblotting and immunofluorescence with and without blocking peptide. The former analysis revealed the presence of a single band of 120 kDa (Fig. lB) , the size of a typical cadherin, in the renal cancer cell line RCC74. Furthermore, the lack of reactivity of this antiserum with E or P-cadherin was demonstrated by immunoblot analysis of cell lines known to be positive for these cadherins (data not shown). antiserum demonstrated immunoreactivity at the cell-cell border (Fig.  1C) , whereas no staining was observed using preimmune rabbit se rum. To demonstrate the specificity of our antibody for cadherin-6, the synthetic peptide used as antigen was added to the primary antibody at different concentrations up to 1 mg/mi. In contrast to the A kb positive staining of normal kidney without the peptide, there was no staining observed at concentrations as low as 0.01 mg/ml. To exclude nonspecific effects, the same peptide was added to anti-E-cadherin antibody, followed by immunohistochemical staining. Under these conditions, staining was unaffected (data not shown). showed positive immunoreaction at the cell-cell border in typical cadherin-like pattern at areas of cell-cell borders but not at cell membranes without cell-cell contact (Fig. 2a) .
Expression of Cadherin-6 in the PrOximal
On frozen sections of normal renal tissue, we could demonstrate staining for cadherin-6 in the renal tubular epithelium at the cell-cell borders (Fig. 2b) . To further characterize this staining in the renal tubular epithelium, serial sections of normal renal tissue were pre pared from surgical specimens and immunohistochemically stained for cadherin-6, F23, and E-cadherin as shown in Fig. 2 , câ€"e. The staining of cadhenn-6 in the renal cortex (Fig. 2d) shows the same distribution as the staining for the membranous glycoprotein F23 (Fig.  2c) , which is specific for the proximal renal tubules (30) . The same 9.5 â€" 7.5 â€" 
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tubules showed positive staining for N-cadherin (data not shown). In contrast, E-cadherin expression was observed in F23-negative tubules, including the distal renal tubules and collecting ducts (Fig. 2e) . No staining of distal tubules and collecting ducts could be observed for cadherin-6, and as expected, proximal tubules were negative for E-cadherin. Except for some scattered positive areas in the Bowman's capsule for all three antibodies used, no cadherin expression could be identified within the glomeruli. The specificity of cadherin-6 positiv ity in the proximal renal tubule, according to F23-positive tubules, was confirmed by immunofluorescence (data not shown). E-cadherin again was restricted to F23-negative distal renal tubules. On higher power, cadherin-6 immunofluorescence (Fig. 3a) ap pears not to be limited to the areas of cell-cell contact but also is present in the areas of the basal membrane. This finding correlates with the localization of the coexpressed ra-catenin (data not shown) and /3-catenin (Fig. 3b) . In contrast, E-cadherin-positive (Fig. 3c) and N-cadherin-positive (Fig. 3d) (33) . To investigate the potential interaction of cadherin-6 with these proteins, we performed immunoprecipitation and immunoconcentration experiments. The au toradiograph of cadherin-6 immunoprecipitates from metabolically labeled RCC74 cells (Fig. 4A) herin-6 or j3-catenin antibody, and by subsequent Western blotting of these immunoprecipitates with either cadherin-6 or J3-catenin antibod ies, we found coprecipitation of /3-catenin with cadherin-6 antiserum, and likewise, cadherin-6 coprecipitated with @-cateninantibody, in dicating their binding interaction in the cell extracts. As negative controls, we used cell extracts immunoprecipitated with nonimmune tissue culture medium prior to Western blotting, as well as substituting culture medium for the cell extract during the immunoprecipitation step (Fig. 4B ). Cadherin-6 Expression In Renal Cancer Cell Lines and Psi mary Renal Cell Carcinomas. We have established two primary renal cancer cell lines from tumors of different histological type. RCC74 is from a papillary renal carcinoma and shows intense expres sion of cadherin-6, and RCC71A is derived from a sarcomatoid renal cell cancer and proved to be cadherin-6 negative. Human renal car cinomas obtained from the ATCC showed different levels of cad herin-6 expression. 769-P and 786-0 showed only very weak staining at the cell-cell borders, but 786-0 demonstrated diffuse cytoplasmic staining, as did Caki-1 and Caki-2 (data not shown).
To examine cadherin-6 expression in primary samples of renal cell cancer, we examined frozen sections for the expression for cadherin-6 and E-cadherin by immunohistochemistry. The samples were scored as either negative (Fig. 5a), positive (Fig. 5b), or heterogeneous (Fig.  5c) . We looked at a total of 32 renal cell cancers stratified by the histological type and tumor grade (Table 1) . Tumors with clear cell features demonstrated cadherin-6 retention in low-grade tumors and heterogeneous or loss of expression in high-grade tumors. All papil lary tumors revealed strong cadherin-6 positivity, whereas sarcoma toid tumors showed loss of cadherin-6 expression. Oncocytomas, which are thought to arise from the collecting duct system (34), proved to be E-cadherin positive and cadherin-6 negative, as would be expected from our observations in normal kidney.
To confirm the results of the immunohistochemistry, Western anal yses were performed. According to the results of the immunofluores cence experiments, RCC74 demonstrated a strong signal for cad herin-6, whereas RCC71A showed no immunoreactivity (Fig. 6A) . No protein signal could be detected for Caki-l and only very faint expression for Caki-2 and 769-P. Of the ATCC cell lines, only 786-0 showed abundant cadherin-6 expression; besides the band at Mr 120,000, several smaller proteins were detected, presumably due to degradation or abnormal products (Fig. 6A ). Attempts to minimize protein degradation by direct solubilization of cultured cells in SDS sample buffer resulted in no change in the pattern of immunoreactive bands. Similar findings have been reported for Ksp-cadherin in the rabbit kidney (35) , although the origin of these smaller polypeptides remains unclear. Three matched pairs of normal renal tissue and renal cell cancer (Fig. 6B) were analyzed demonstrating either up-regulation (sample 140), equal expression (sample 246), or no expression (sample 273) of cadherin-6 in renal tumors compared to normal. On histological examination of these tumors, the two cadherin-6-positive tumors revealed clear cell features, whereas the cadherin-6-negative tumor was an oncocytoma.
DISCUSSION
In this study, we demonstrate that cadherin-6 is specifically cx pressed in the proximal renal tubule in human kidney. Cadherin-6 shows two features typical of classical cadherins: (a) staining at the cell-cell border at the areas of cell-cell contact; and (b) interaction with the cytoplasmic proteins a-and j.3-catenin. Furthermore, we examined a series of primary renal cell cancers, finding that loss of cadherin-6 expression is more common in high-grade tumors or tumors with worse prognosis. These observations implicate a possible role of cadherin-6 as an important factor in renal tumor progression.
To understand the development and progression of a given cancer ,@ -1 b @ â€˜@:â€" â€"â€˜@ Terpe et a!. (14) demonstrated that E-cadherin expression can be found in about 30% of all renal tumors and is restricted to low-grade cancers; they suggested that E-cadherin expression may be connected to a dedifferentiation process. Katagiri et a!. (15) also investigated E-cadherin expression in renal tumors. They found that none of the metastasis expressed E-cadherin, but about 20% of the primary lesions showed positive immunoreactivity. The authors conclude that E cadherin may be a prognostic marker in renal cell cancer, but because of the low rate of expression, other cell adhesion molecules may play a more important role. N-cadherin, also called A-CAM, which is known to be expressed during the renal development and in the proximal renal tubules of the adult kidney (40) , has also been inves tigated. Tani et a!. (16) reported that E-and N-cadherin expression in renal cell cancer does not correlate with tumor grade. They concluded that aberrations in another pathway must be responsible for the deficient capacity to form polarized tubular structures in kidney cancer. A novel cadherin molecule, cadherin-6, was isolated by Shi moyama et al. (19) from a hepatocellular carcinoma lacking E-and P-cadherin expression. This cadherin showed 97% homology with the cDNA of K-cadherin, which was cloned by Xiang et a!. (20) from a rat renal cancer cell line. K-cadherin could not be detected in adult rat kidneys, but RNA transcripts of human cadherin-6 were found by Northern analysis of adult human kidneys and renal cancer cell lines (19) . These first reports suggested that cadherin-6 is involved in the development of the kidney and possibly renal cell cancer.
Our results confirm the tissue specificity of cadherin-6 and estab lish for the first time that cadherin-6 is expressed in the proximal tubular epithelium. The distribution of cadherin-6 shows typical stain ing at the cell borders in areas of cell-cell contact in vitro. In vivo we observed that cadherin-6 is also localized at the basal membrane, along with /3-catenin. We speculate that cadherin-6, which is specif have been suggested to originate from the collecting duct (46) , al though studies are contradictory regarding both these issues (47) . Homogeneous staining for cadherin-6, however, is more consistent with the origin of these tumors from the proximal renal tubule and may explain the unusual papillary structure of polarized cells in contrast to solid clear cell carcinomas. However, the use of cell specific markers to determine cell type of origin can be problematic, and it is certainly possible that acquisition of cadherin-6 expression accompanies cellular transformation in this tumor type. The renal tumor with the most favorable prognosis (48) , the oncocytoma, is cadherin-6 negative, but this tumor has been shown to arise most likely from the collecting duct (34) , and thus, cadherin-6 expression would not be expected.
In conclusion, we demonstrate that cadherin-6 is specifically cx pressed in the proximal renal tubules in humans. Cadherin-6 is re tamed in some but not all renal cell carcinomas. The observation of differential expression of cadherin-6 in renal cancers of different histological type and tumor grade and down-regulation of expression in a significant subset of renal cell carcinomas is consistent with an involvement of this cell adhesion molecule in the progression of renal cell cancer. Additional, direct studies of cadherin-6 dysfunction in renal cell carcinoma will be necessary to expand these findings and to fully elucidate the role of this process in renal cell cancer progression. Because the majority of renal cell carcinomas are thought to arise from the proximal renal tubular epitheium (12, 42) (43, 45) , and these tumors dem onstrated more heterogeneous cadherin-6 reactivity in our study.
Papillary renal carcinomas demonstrated uniform positive staining.
These tumors, which tend to have a more favorable prognosis (13),
